News


All series


All News

A new study shows comparability between liquid biopsy and tissue biopsy in both diagnostics and monitoring of non&ndash;small cell lung cancer (NSCLC). However, based on the results, liquid biopsies may be preferable to help oncologists make swifter decisions that help manage the disease.<br /> &nbsp;

The Cancer Research Institute announced 5 US scientists accepted into their inaugural CRI Lloyd J. Old STAR Program for taking on potentially transformative research in cancer immunology. The scientists were announced at the CRI&rsquo;s recent &ldquo;Immuno-Oncology: A Future Look&rdquo; event at the New York Academy of Sciences, which also recognized and celebrated the seventh annual Cancer Immunotherapy Month.

In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for&nbsp;bevacizumab across several indications.

An updated systematic review and new meta-analysis of the incidence of subsequent malignant neoplasms following thyroid cancer has found that there was no significant increased relative risk of breast cancer, salivary cancer, or combined hematologic malignancies based on whether or not patients had received radioactive iodine.

The FDA has approved Zirabev, a biosimilar to bevacizumab for 5 indications.&nbsp;Zirabev has been approved for the treatment of patients with metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non&ndash;small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Frontline durvalumab led to a statistically significant and clinically meaningful improvement in overall survival (OS) in combination with etoposide and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer, according to the results of a planned interim analysis of the phase III CASPIAN trial.

Significant activity was observed when ibrutinib was administered concurrently with CD19-directed CAR T-cell therapy compared with separately in patients with&nbsp;high-risk relapsed/refractory chronic lymphocytic leukemia who had progressed on or were intolerant of ibrutinib.&nbsp;Data presented at the 15th International Conference on Malignant Lymphoma show a high response rate with this concurrent treatment.&nbsp;